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Abstract
Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that regulates a plethora of downstream signaling
pathways essential for cell migration, proliferation and death, processes that are exploited by cancer cells during
malignant progression. These well-established tumorigenic activities, together with its high expression and activity in
different cancer types, highlight FAK as an attractive target for cancer therapy. We have assessed and characterized the
therapeutic potential and the biological effects of BI 853520, a novel small chemical inhibitor of FAK, in several
preclinical mouse models of breast cancer. Treatment with BI 853520 elicits a signiﬁcant reduction in primary tumor
growth caused by an anti-proliferative activity by BI 853520. In contrast, BI 853520 exerts effects with varying degrees
of robustness on the different stages of the metastatic cascade. Together, the data demonstrate that the repression of
FAK activity by the speciﬁc FAK inhibitor BI 853520 offers a promising anti-proliferative approach for cancer therapy.
Introduction
Every year, more than 1.4 million women worldwide are
diagnosed with breast cancer, and over 450,000 women
will lose their lives to this disease, mostly due to metas-
tasis1. Over the past decades, we have gained many
important insights into breast cancer biology, which in
turn have allowed the development of therapeutic
approaches targeting molecules and signaling pathways
speciﬁcally present in breast cancer cells2,3. Previous
studies have linked the overexpression and activation of
focal adhesion kinase (FAK) with the initiation and pro-
gression of a wide variety of malignancies, such as ovarian,
head and neck, and breast carcinoma2–6. FAK is a mul-
tifunctional cytoplasmic tyrosine kinase that forms an
important component of focal adhesion sites7–11. Once
recruited by signals initiated at integrin-mediated
extracellular matrix attachment sites and by multiple
growth factor receptors, such epithelial growth factor
receptor, vascular endothelial growth factor receptor, and
platelet-derived growth factor receptor, FAK undergoes a
conformational change, enabling autophosphorylation of
the tyrosine residue (Y) 397 at its N-terminal
domain3,12,13. Subsequently, phosphorylated Y397 serves
as a docking site for SRC homology 2 containing SRC
family kinases, which results in a fully active FAK-SRC
signaling complex that can trigger various downstream
signaling pathways known to control cell migration,
invasion, proliferation, and death—all activities pivotal for
malignant tumor progression3,7,10,11,14–18.
Previous studies have indicated that the forced expres-
sion of FAK in endothelial cells enhances angiogenesis
and that the ectopic expression of a constitutive-active
form of FAK in murine mammary cancer cells promotes
their proliferation. Conversely, decreasing FAK expres-
sion impairs cancer cell proliferation in vitro and
in vivo6,10,19–21 and inhibits endothelial cell proliferation
in vitro and in vivo. These data together suggest a linear
relationship between FAK activity and
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tumorigenesis8,19,20,22,23. However, a recent study has
reported that the heterozygous depletion of FAK in
endothelial cells increases endothelial cell proliferation
and tumor angiogenesis, indicating a non-linear effect of
FAK activity in carcinogenesis3,19,20. Supporting this
notion, low-dose treatment with the FAK inhibitor (FAK-
I) PF-573228 increases microvessel sprouting ex vivo and
tumor growth in vivo19. These results indicate that the
causal link between FAK activity and tumor progression
still escapes a ﬁnal conclusion, and further investigations
are warranted to delineate the functional contribution of
FAK to carcinogenesis.
We have evaluated the therapeutic and biological effects
of BI 853520, a novel, potent, and selective small chemical
entity kinase FAK-I24, in cultured murine breast cancer
cells in vitro and in various transplantation and transgenic
mouse models of breast cancer in vivo. Gene expression
proﬁling of primary tumors of mice treated with BI
853520 reveals a decrease in the expression of genes
regulating cell proliferation. Indeed, treatment with BI
853520 provokes a signiﬁcant reduction in cell prolifera-
tion in vitro and in vivo. In contrast, BI 853520 exerts
heterogeneous effects on pulmonary metastasis at differ-
ent levels of the metastatic cascade depending whether it
is used in a neoadjuvant or adjuvant therapeutic setting.
Thereby, the epithelial cell adhesion molecule E-cadherin
may serve as a potential predictive marker for increased
sensitivity of cancer cells to treatment with BI 853520.
Results
The FAK-I BI 853520 represses Y397-FAK
autophosphorylation
To determine the in vitro efﬁcacy of the FAK-I BI
853520 in repressing Y397-FAK phosphorylation in dif-
ferentiated breast cancer cells and in breast cancer cells
that have undergone an epithelial–mesenchymal transi-
tion (EMT) and also to test the generality of the ﬁndings,
we employed a combination of various murine mammary
cancer cell lines. 4T1 cells, which have been derived from
a spontaneous tumor in a mammary gland of a Balb/c
mouse, show hallmarks of a partial EMT and are highly
metastatic upon transplantation into mice. The Py2T cell
line has been established from a tumor of a MMTV-
PyMT transgenic mouse. Py2T cells exhibit an epithelial
cell morphology and undergo a reversible EMT upon
long-term treatment with transforming growth factor-β
(TGFβ) in vitro (Py2T-LT cells)25. 4T1, Py2T, and Py2T-
LT cells were treated with different concentrations of BI
853520, and Y397-FAK phosphorylation was assessed by
immunoblotting analysis and immunoﬂuorescence stain-
ing using a phospho-Y397-FAK-speciﬁc antibody. BI
853520 signiﬁcantly reduces Y397-FAK autopho-
sphorylation in all cell types (Fig. 1a, b), while the phos-
phorylation levels of FAK’s homolog PYK2 remained
unaffected up to micromolar concentrations (Fig. 1a).
Next, a time-course experiment was performed on
4T1 cells treated for various time points with 0.1 µM BI
853520 to analyze FAK-I efﬁcacy in a time-dependent
manner. Decreased Y397-FAK autophosphorylation fol-
lowing 0.1 µM BI 853520 treatment occurred within
10min and was substantially reduced at least for the
following 48 h (Fig. 1c), demonstrating a fast and potent
inhibition of FAK by BI 853520 in this highly metastatic
murine breast cancer cell line.
BI 853520 represses tumor cell proliferation and invasion
only in 3D culture
We next assessed the repressive effect of the FAK-I BI
853520 on proliferation and invasion of 4T1 cells,
Py2T cells and Py2T cells that have undergone an EMT
(Py2T-LT). When cultured in two-dimensional (2D)
plastic dishes, epithelial Py2T cells and mesenchymal
Py2T-LT cells did not show any change in cell mor-
phology or proliferation upon treatment with up to 3 µM
BI 853520. However, at a concentration of 10 µM and
above a cytotoxic effect, a massive apoptosis could be
observed with both cell types (Fig. 1d).
To further investigate the repressive effect of BI 853520
on breast cancer cell proliferation in vitro, we conducted
an MTS assay on 4T1, Py2T, and Py2T-LT cells as pre-
viously reported (Suppl. Figure 1A)26. Increasing con-
centrations of BI 853520 led to a modest yet signiﬁcant
reduction in cell viability of all three breast cancer cell
types grown in 2D already at 10–100 nM, with a massive
reduction at the toxic concentrations above 3 μM. Flow
cytometry-based 5-ethynyl-2′-deoxyuridine/propidium
iodide (EdU/PI) cell cycle analysis of 4T1 cells revealed a
shift in cells leaving the S phase and entering the G1 phase
(Suppl. Figure 1B). Consistent with these results, the
percentage of phospho-histone 3 (pH3)-positive nuclei
was decreased in 4T1 cells with increasing concentrations
of BI 853520, while increased rates of apoptosis were only
observed at the toxic concentration of 10 μM BI 853520
(Suppl. Figure 1C, D).
In contrast, when cultured in a 3D environment, such as
in soft agar, colony formation of mesenchymal Py2T-LT
started to be compromised already at a concentration of
1 nM BI 853520 (Fig. 1e). Epithelial Py2T cells did not
form colonies in this assay even in the absence of BI
853520 (data not shown).
We have previously reported that mesenchymal Py2T-
LT cells show a massive invasion into the surrounding
matrix when cultured in 3D in Matrigel, while epithelial
Py2T cells form highly differentiated spheres25 (Fig. 1f and
Suppl. Figure 1E). Comparable invasive growth was also
observed with 4T1 cells when cultured in Matrigel (Suppl.
Figures 1E, 2A). The invasion of mesenchymal Py2T-LT
cells was already inhibited at 10 nM BI 853520, while
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sphere formation of epithelial Py2T cells was only affected
by increased cell death at the toxic concentrations of BI
853520 higher than 1 μM (Fig. 1f). This effect was not as
pronounced with 4T1 cells cultured in Matrigel, where BI
853520 at doses above 0.1 μM repressed cell invasion,
although without statistical signiﬁcance, while high doses
exerted a toxic effect (Suppl. Figure 1E). The efﬁcient
repression of FAK autophosphorylation in the 3D
Matrigel cultures was determined by immuno-
ﬂuorescence staining of the spheroids and by immuno-
blotting of spheroid lysates (Suppl. Figure 2A, B). Despite
a decrease in cell invasion, the immunoﬂuorescence and
immunoblotting analysis revealed that FAK inhibition did
not substantially affect the expression of the mesenchymal
markers ﬁbronectin, vimentin, or Zeb1 and the epithelial
markers E-cadherin or ZO1 in the spheroid cultures.
These results indicate that the speciﬁc inhibition of cell
proliferation and invasion at low doses of BI 853520 is
functional only in three-dimensional cell culture condi-
tions, whereas cells cultured on plastic only respond to BI
853520 at very high, toxic doses of BI 853520.
BI 853520 attenuates primary tumor growth
To examine the repressive effect of the FAK-I BI 853520
on primary tumor growth in vivo, we have employed a
variety of cellular and transgenic and transplantation
mouse models of breast cancer. MMTV-PyMT transgenic
mice develop mammary gland tumors and recapitulate
the stepwise progression from differentiated mammary
gland epithelia to hyperplasia, adenoma, carcinoma, and
lung metastasis27. Py2T murine epithelial breast cancer
cells are highly tumorigenic and gain mesenchymal
characteristics when implanted into mice in vivo, yet they
are rarely metastatic25. 4T1 cells are highly metastatic
breast cancer cells derived from a spontaneous mammary
gland tumor of a Balb/c mouse28. Finally, E-cadherin-
proﬁcient MTﬂECad cells have been isolated from a
lymph node metastasis of a MMTV-Neu;Cdh1ﬂ/ﬂ tumor-
bearing mouse and have been infected with an adenovirus
expressing Cre recombinase to obtain the E-cadherin-
deﬁcient cell line MTΔECad29.
Py2T, 4T1, or MTﬂECad breast cancer cell lines were
orthotopically transplanted into the mammary fat pad of
syngeneic FVB/N, Balb/c, or immunodeﬁcient nude (nu/
nu) mice, respectively, and mice were treated with 50mg/
kg BI 853520 by oral gavage. BI 853520 treatment sig-
niﬁcantly suppressed primary tumor growth of all three
cell lines in vivo (Fig. 2a–c and Suppl. Figure 3A, B).
Together, the data suggest a model-independent sup-
pression of primary tumor growth by BI 853520 which is
consistent with data shown by Hirt et al30,31. Consistent
with the results from experiments with cultured cell lines
in vitro (Fig. 1a, c), immunoblotting analysis of primary
Py2T tumors of mice treated with BI 853520 for 3 days
displayed a decrease in the levels of Y397-FAK phos-
phorylation (Suppl. Figure 3C). Similarly, Y397-FAK
phosphorylation levels were reduced, although not with
statistical signiﬁcance, when mice bearing 4T1 tumors
were treated with a single dose of BI 853520 and sacriﬁced
1, 4, or 8 h post treatment (Suppl. Figure 3D).
Fig. 1 BI 853520 decreases Y397-FAK phosphorylation in a dose-dependent and time-dependent manner. a To determine the effective dose
of BI 853520, 4T1, Py2T, and Py2T-LT cells were exposed to increasing concentrations of BI 853520 (0, 0.1, 0.5, 1, 5, and 10 µM for 4T1 cells; 1, 3, and
10 µM for Py2T and Py2T-LT cells) for 24 h. Top left panel: 4T1 cell lysates were examined by immunoblotting analysis for phospho-FAK-Y397 (pFAK)
and total FAK (FAK). GAPDH served as a loading control (n= 4). Immunoblotting for phospho-PYK2-Y402 (pPYK2), total PYK2 (PYK2), and GAPDH and
tubulin as loading control is shown in the top middle panel (n= 2). Top right panel: Quantiﬁcation of pFAK signal intensity normalized to GAPDH and
total FAK/GAPDH ratios from the immunoblotting analysis shown on the left. Statistical analysis was performed using an unpaired, two-tailed
Student’s t test. ****p < 0.0001, ***p < 0.001. Bottom left panel: Py2T and Py2T-LT cell lysates were examined by immunoblotting analysis for phospho-
FAK-Y397 (pFAK). GAPDH served as a loading control (n= 1). Right panel: Quantiﬁcation of pFAK signal intensity normalized to GAPDH from the
immunoblotting analysis shown on the left. b 4T1 cells grown on coverslips were treated with the effective dose of BI 853520 (0.1 µM) for 96 h,
followed by immunoﬂuorescence staining for pFAK (Y397, green), total FAK (red), and DNA (blue). Images were obtained using a laser-scanning
confocal microscope Leica SP5 (n= 2). Scale bar, 30 µm. c To determine the onset and duration of BI 853520-mediated pFAK downregulation,
4T1 cells were treated for the times indicated with 0.1 µM BI 853520. Cell lysates were analyzed by immunoblotting for pFAK (Y397), total FAK, and
GAPDH as a loading control (n= 3). Right panel: Quantiﬁcation of pFAK signal intensity normalized to GAPDH and total FAK/GAPDH ratios from the
immunoblotting analysis shown on the left. Statistical analysis was performed using an unpaired, two-tailed Student’s t test. ***p < 0.001, **p < 0.01,
and *p < 0.05. d Cytotoxic effects of high doses of BI 853520 on murine breast cancer cells cultured on plastic surface. Epithelial Py2T and
mesenchymal Py2T-LT murine breast cancer cells were treated with BI 853520 at the concentrations indicated and phase contrast micrographs were
taken. Cells were then suspended, and staining for Annexin-V as marker of apoptosis was quantiﬁed by ﬂow cytometry (n= 2). Statistical analysis was
performed using an unpaired, two-tailed Student’s t test. ****p < 0.0001. Scale bar: 120 μM. e BI 853520 represses colony formation in three-
dimensional growth conditions. Py2T-LT cells were seeded in soft agar gels and treated with increasing concentrations of BI 853520 as indicated. The
numbers of colonies were quantiﬁed. (n= 3). Unpaired, two-tailed Student’s t test. ****p < 0.0001, *p < 0.05. f BI 853520 represses mesenchymal
murine breast cancer cell invasion cultured in Matrigel. Epithelial Py2T and mesenchymal Py2T-LT murine breast cancer cells were seeded in Matrigel
and treated with increasing concentrations of BI 853520 as indicated. Phase contrast microscopy pictures were taken and the numbers of invasive
colonies were quantiﬁed. Epithelial Py2T cells formed differentiated spheres which only responded to BI 853520 at high, toxic concentrations (n= 1).
Statistical analysis was performed using an unpaired, two-tailed Student’s t test. *p < 0.05. Scale bar: 60 μM. ns not signiﬁcant
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Fig. 2 BI 853520 decreases primary tumor growth in various orthotopic pre-clinical mouse models of breast cancer. a Oral treatment of
mice bearing Py2T breast tumors with daily 50 mg/kg BI 853520 dissolved in Natrosol or with Natrosol-vehicle alone from day 22 post injection
(indicated by an arrow) for 25 consecutive days signiﬁcantly decreased tumor volume over time. n= 10 mice per treatment cohort. b Oral treatment
of mice bearing 4T1 breast tumors with daily 50 mg/kg BI 853520 dissolved in Natrosol or with Natrosol-vehicle alone from day eight post injection
(indicated by an arrow) signiﬁcantly decreased tumor volume over time. Tumor growth curves of individual mice are shown. Vehicle cohort, n= 7
mice; BI 853520 cohort, n= 6 mice. c Oral treatment of mice bearing MTﬂECad breast tumors with daily 50 mg/kg BI 853520 dissolved in Natrosol or
with Natrosol-vehicle alone from day 10 post injection signiﬁcantly decreased tumor volume over time (indicated by an arrow). n= 9 mice per
treatment cohort. d Top: Oral treatment schedule for the treatment of MMTV-PyMT transgenic mice with vehicle, BI 853520-late (50 mg/kg daily, from
10 to 13 weeks of age) or BI 853520-early (50 mg/kg daily, from 5 to 13 weeks of age). Bottom: Normalized mammary fat pad (MFP) weights for each
treatment cohort. All mice were sacriﬁced at 13 weeks of age, and primary tumors and lungs were used for further analysis. Vehicle cohort, n= 9; BI
853520-late, n= 9; BI 853520-early, n= 8. e Early BI 853520 treatment signiﬁcantly improves tumor-free survival of MMTV-PyMT mice. Days on
treatment starting from week 5 of age are shown. The time reaching termination criteria was determined for the mice treated as described in d. As
shown here, at the time point of treatment initiation of the BI 853520-late group (arrow; day 35 on treatment), most mice in this group displayed
palpable tumors. f Grading of primary tumors of MMTV-PyMT transgenic mice treated as described in d. Data are shown as the percentage of the
average area covered by each grade of two histological sections per mouse. Early BI 853520 treatment delays malignant tumor progression (increase
in hyperplasia and adenoma stage, decrease in carcinoma stage). Statistical analysis was performed by unpaired, two-tailed Mann–Whitney U test (a,
c, d), by log-rank (Mantel–Cox) test (e), and unpaired, two-tailed Student’s t test (f). All data are depicted as means ± SEM. ****p < 0.0001, ***p < 0.001,
**p < 0.01, *p < 0.05
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Since transplantation models of cancer cell lines lack
the multi-step development of tumors as observed in
patients, we next tested the effect of BI 853520 on primary
tumor growth and progression in the MMTV-PyMT
transgenic mouse model of metastatic breast cancer, a
valuable tool to investigate metastatic breast cancer
development and progression27. Strikingly, both the
administration of BI 853520 at an early stage of tumor
development (5 weeks of age; “BI 853520 early”) and at
10 weeks of age (“BI 853520 late”), a time point when
most MMTV-PyMT mice had palpable tumors, sig-
niﬁcantly reduced mammary fat pad weight as a surrogate
endpoint for total tumor burden per mouse (Fig. 2d).
Notably, administration of BI 853520 at 5 weeks of age
signiﬁcantly delayed the development of palpable tumors,
that is, tumor-free survival (Fig. 2e). In addition, BI
853520 inhibited tumor progression by reducing the for-
mation of invasive carcinomas within the primary tumors
of the transgenic mice (Fig. 2f). In summary, the FAK-I BI
853520 exerts a potent capability to repress primary
tumor growth and tumor progression in multiple mouse
models of breast cancer.
BI 853520 restrains tumor cell proliferation
In order to delineate the molecular mechanisms leading
to the therapeutic effect of BI 853520 on primary tumor
growth, mice harboring 4T1 primary tumors were treated
for 5 days with BI 853520, and RNA extracted from total
tumors was subjected to next-generation sequencing.
Only primary tumors with sufﬁcient RNA quality were
included into further analysis (Suppl. Figure 4A). Gene
expression correlation analysis displayed a clear separa-
tion of transcriptomic proﬁles derived from primary
tumors of mice treated with BI 853520 or vehicle (Suppl.
Figure 4B). Comparative gene expression analysis of pri-
mary tumors of mice treated with BI 853520 vs. vehicle
control revealed 1293 upregulated and 475 downregulated
genes (cutoffs: p value ≤0.05, fold change ±1.5). Func-
tional enrichment analysis for biological processes and
signaling pathways indicated that the regulation of epi-
thelial cell proliferation and positive regulation of cell
cycle/cell proliferation/cell division were enriched in
genes downregulated by BI 853520 treatment (Fig. 3a). In
line with this ﬁnding, gene set enrichment analysis con-
ﬁrmed a signiﬁcant reduction in the relative expression of
genes important for cell cycle and positive regulation of
mitotic cell cycle (including cyclin-dependent kinase 1
and 4; Cdk1: log 2 fold change=−0.4519, false discovery
rate (FDR)= 4.24e−03; Cdk4: log 2 fold change=
−0.3072, FDR= 0.003718), while the negative regulation
of cell proliferation was increased following BI 853520
treatment (Fig. 3c and Suppl. Figure 4C). Interestingly,
biological processes linked to T cell differentiation and
cell proliferation, (acute) inﬂammatory response, cytokine
production, and leukocyte activation were enriched in the
group of genes upregulated by BI 853520 treatment (Fig.
3b).
In order to validate the anti-proliferative mechanism of
BI 853520 on primary tumor growth, we analyzed the
proliferation marker pH3 on histological sections of
tumors from mice orthotopically transplanted with
Py2T cells and treated with BI 853520 for a short term.
Immunostaining for pH3 demonstrated a signiﬁcant
reduction of pH3-positive nuclei per area in mice treated
with BI 853520 (Fig. 4a). Similarly, in both the 4T1 breast
cancer model and the MMTV-PyMT transgenic mouse
model, BI 853520 treatment led to a signiﬁcant decrease
in pH3-positive nuclei per mm2 (Fig. 4b, c). In contrast,
apoptosis as assessed by immunoﬂuorescence staining for
cleaved caspase-3 (cCasp3) was not signiﬁcantly affected
in the transgenic mouse model and in the short-term
Py2T breast cancer model (Fig. 4c, d). In the 4T1 model,
inter-experimental variability of cCasp3 staining and thus
of the rate of apoptosis did not allow a reliable conclusion.
Immunoﬂuorescence staining of histological sections
from the 4T1 tumors for blood vessel density (CD31), for
vessel perfusion (FITC-Lectin perfusion), for vessel lea-
kiness (FITC-Dextran), and for tumor hypoxia (Pimoni-
dazole) did not reveal any signiﬁcant changes (Suppl.
Figure 5A–D).
Consistent with the ﬁndings on murine breast cancer
cells cultured in vitro, these results indicate that the
repressive effect of BI 853520 on tumor growth is attri-
butable to its anti-proliferative mode of action on tumor
cells.
Heterogeneous effects of BI 853520 at different stages of
the metastatic cascade
Most studies have primarily focused on primary tumor
growth when validating novel anti-cancer compounds, yet
metastasis is the major cause of morbidity and mortality.
To this end, we performed an in-depth analysis of BI
853520's effect on the different stages of the metastatic
process, employing the 4T1 transplantation model of
breast cancer that predominantly metastasizes to the lung.
Assuming that the metastatic process involves the inter-
play between cancer cells and cell types of the tumor
microenvironment, we orthotopically injected 4T1 cells in
BALB/c mice and started BI 853520 treatment 3 days
before (BI 853520 PRE) or 7 days post 4T1 cell implan-
tation (BI 853520 POST). Both treatment regimens efﬁ-
ciently reduced primary tumor volume (Fig. 5a). Notably,
BI 853520 PRE-treated 4T1 tumors were signiﬁcantly
delayed in their initial growth, since they were palpable
only at later time points as compared to the vehicle-PRE-
treated control cohort (Suppl. Figure 6A). Interestingly,
even though BI 853520 post treatment led to a signiﬁcant
decline in 4T1 tumor volumes, pulmonary metastasis
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numbers per section and the metastasis area fraction were
only decreased in the BI 853520 PRE cohort (Fig. 5a and
Suppl. Figure 6B). This result suggests that once 4T1
tumor cells have entered the lung parenchyma and pro-
liferation has been initiated, BI 853520 treatment does no
longer reduce the number of metastatic nodules. To test
this hypothesis, 4T1 tumor cells were injected intrave-
nously (i.v.) into the tail vein of mice to bypass the pro-
cesses of primary tumor colonization and intravasation. BI
853520 treatment was either initiated 3 days before i.v.
Fig. 3 BI 853520 treatment downregulates genes implicated in cell proliferation and upregulates genes implicated in immune response.
a, b List of biological processes enriched in downregulated and upregulated genes, respectively, upon treatment of mice bearing primary 4T1 tumors
with 50 mg/kg BI 853520 dissolved in Natrosol-vehicle or vehicle alone for 5 days. All terms shown in the bar graphs are statistically signiﬁcant (p
value ≤0.05). The blue and red bars represent p values in −log 10 format and the fold enrichment for each term, respectively. The p values and
enrichment were computed using Fisher’s exact test. c Box whisker plots showing the relative expression of genes involved in processes of cell cycle,
positive regulation of mitotic cell cycle, and negative regulation of cell proliferation that were identiﬁed using gene set enrichment analysis. Relative
gene expression was compared between vehicle-treated group (n= 3) and BI 853520-treated group (n= 6). The signiﬁcance between the groups is
shown as p values using an unpaired, two-tailed Student’s t test. ***p < 0.001, **p < 0.01, and *p < 0.05
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tumor cell injection (BI 853520 PRE) or 3 days after i.v.
injection of tumor cells (BI 853520 POST)—a time point
when metastatic clones have already started proliferating
in the lung (Suppl. Figure 6C). Indeed, pre-treating the
mice before i.v. tumor cell injection reduced the number
of metastasis and the metastatic area fraction (Fig. 5b).
However, initiating BI 853520 treatment after metastasis
had started to form did not signiﬁcantly reduce the
number of metastasis but decreased metastatic nodule
size, as suggested by the reduced metastatic area fraction
(Fig. 5b), consistent with BI 853520's anti-proliferative
activity.
The latter result would argue that BI 853520 may not be
able to suppress the metastatic seeding of breast cancer
cells, but rather inhibit outgrowth of already seeded
metastatic modules. To test this possibility, we performed
an experiment in which primary tumors were surgically
resected 14 days after orthotopic implantation of
4T1 cells, and BI 853520 treatment was initiated 2 days
later. Surprisingly, the number of metastatic nodules was
increased; however, the metastatic area fraction was
slightly reduced, yet without statistical signiﬁcance (Fig.
5c and Suppl. Figure 6D). When 4T1-transplanted mice
were treated with BI 853520 before surgical removal of
the primary tumor and then therapy was stopped, primary
tumor growth and also the number of metastasis were
reduced, although without statistical signiﬁcance (Fig. 5d).
However, when reduced primary tumor growth was
normalized to the number of metastasis (metastatic
index), no signiﬁcant change in the number of metastasis
between BI 853520-treated and control-treated mice
could be observed (Suppl. Figure 6E).
A similar overall lack of signiﬁcant suppression of
metastasis by BI 853520 was also seen in the MMTV-
PyMT mouse model of metastatic breast cancer.
Although primary tumor growth and tumor progression
was strongly reduced (Fig. 2d), the number of metastases
was unchanged regardless of initiating BI 853520 treat-
ment at an early or a late stage of multi-step carcino-
genesis (Suppl. Figure 6F). However, comparable to the
4T1 highly metastatic, syngeneic transplantation model of
breast cancer, in the MMTV-PyMT transgenic mouse
model of stepwise breast cancer progression and metas-
tasis, the percentage of large metastases was signiﬁcantly
reduced by long-term BI 853520 treatment (Suppl. Figure
6F), suggesting that BI 853520 repressed metastatic tumor
cell proliferation. Together, these results indicate that BI
853520 rather represses tumor cell proliferation than
metastatic dissemination and that BI 853520 seems to
exert heterogeneous effects on metastasis formation
depending on the time and the stage of the metastatic
cascade when BI 853520 is ﬁrst administered.
E-cadherin status-dependent effects by BI 853520
FAK is seen as a key mediator in the crosstalk of
integrin-mediated cell–matrix and E-cadherin-mediated
cell–cell contacts—central mechanisms involved in can-
cer cell invasion and metastasis32. In order to study the
inﬂuence of the E-cadherin status and, with it, of an EMT
on the cells’ susceptibility to BI 853520, we employed the
E-cadherin-proﬁcient and E-cadherin-deﬁcient murine
breast cancer cell lines MTﬂECad and MTΔECad,
respectively. MTﬂECad cells exhibit a fully differentiated
epithelial cell phenotype, while the genetic ablation of E-
cadherin expression in MTΔECad resulted into a com-
plete EMT, as manifested by changes in marker gene
expression and a gain in the cells’ migratory, invasive, and
metastatic capabilities29. MTﬂECad and MTΔECad cells
Fig. 4 Reduced primary tumor growth is due to an anti-proliferative effect of BI 853520. a Immunoﬂuorescence microscopy analysis of
primary tumor sections of Py2T breast tumors of mice treated for 3 days with vehicle control or with daily 50 mg/kg BI 853520 for phospho-histone 3
(pH3; red) and DAPI (cell nuclei; blue). Quantiﬁcation of pH3-positive nuclei per mm2 is shown on the left, representative immunoﬂuorescence
images are shown on the right. n= 5 tumors in the vehicle group, n= 3 tumors in the BI 853520-treated group. b Immunoﬂuorescence microscopy
analysis of primary tumor sections of 4T1 breast tumor bearing mice treated with vehicle control or daily 50 mg/kg BI 853520 and analyzed at the
experimental end point as shown in Fig. 2b for pH3 (red) and DAPI (cell nuclei; blue). Quantiﬁcation of pH3-positive nuclei per mm2 is shown on the
left, representative immunoﬂuorescence images are shown on the right. n= 4 tumors in the vehicle group, n= 3 tumors in the BI 853520-treated
group. Due to the widespread necrotic areas in this tumor model, only areas with intact cell nuclei were assessed. c Left panel: number of pH3-
positive nuclei per mm2 on primary tumor sections from MMTV-PyMT transgenic mice following treatment with vehicle alone, daily 50 mg/kg BI
853520-late (from 10 to 13 weeks of age) or daily 50 mg/kg BI 853520-early (from 5 to 13 weeks of age) as described in Fig. 2d. n= 4 tumors in the
vehicle group, n= 5 tumors in the BI 853520-late group, and n= 5 tumors in the BI 853520-early group. Right panel: Number of cleaved caspase-3
(cCasp3)-positive nuclei per mm2 of primary tumor sections from MMTV-PyMT transgenic mice following BI 853520 treatment. n= 5 tumors in the
vehicle group, n= 6 tumors in the BI 853520-late group and n= 7 tumors in the BI 853520-early group. Due to the massive difference in cellularity
between different tumor areas in this particular tumor model, pH3, and cCasp3 counts were corrected to the area covered by DAPI-staining as a
surrogate for cellularity. d Immunoﬂuorescence microscopy analysis of primary tumor sections of Py2T breast tumor-bearing mice treated for 3 days
with vehicle control or 50 mg/kg daily BI 853520 for cleaved caspase 3 (cCasp3; red) and DAPI (cell nuclei; blue). Quantiﬁcation of cCasp3-positive
nuclei per mm2 is shown on the left, representative immunoﬂuorescence images are shown on the right. n= 5 tumors in the control group and n=
3 tumors in the BI 853520-treated group. Data indicate counts per ﬁeld of view, shown as mean ± SEM. Statistical difference was determined by the
unpaired, two-tailed Student’s t test. ****p < 0.0001, **p < 0.01. ns not signiﬁcant
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Fig. 5 (See legend on next page.)
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were orthotopically injected into immunodeﬁcient
Rag2−/−;γc−/− mice, and BI 853520 treatment was initi-
ated when tumors reached the size of 100mm3 and
continued until tumors measured ~1500mm3. Strikingly,
BI 853520 treatment signiﬁcantly delayed primary tumor
growth of the highly differentiated, E-cadherin-proﬁcient
and non-metastatic MTﬂECad tumors (Fig. 6a, b), as
already described above (Fig. 2c). In contrast, the growth
of E-cadherin-deﬁcient, invasive and metastatic MTΔE-
Cad tumors was not apparently affected by treatment with
BI 853520 (Fig. 6a, b). Notably, BI 853520 reduced the
number of metastasis in the lungs of mice transplanted
with MTΔECad cells (Fig. 6c), whereas MTﬂECad did not
form metastasis even in the absence of BI 853520 (data
not shown).
In summary, the data suggest that BI 853520 is more
potent in repressing tumor cell proliferation and primary
tumor growth of differentiated, E-cadherin-expressing
tumor cells (MTﬂECad, Py2T, in parts 4T1 cells and early
stages of MMTV-PyMT tumor progression), while it
represses the metastatic outgrowth of invasive, E-
cadherin-deﬁcient tumor cells (MTΔECad and late
stages/metastasis of MMTV-PyMT tumor cells). The loss
of E-cadherin expression is a hallmark of an EMT. While
an EMT is mainly responsible for primary tumor cell
invasion, its reversal, a mesenchymal–epithelial transition
(MET), has been shown to contribute to the metastatic
outgrowth of disseminated cancer cells in distant organs.
Hence, the repressive effect of BI 853520 on metastatic
outgrowth may be a result of the more potent anti-
proliferative effect of BI 853520 on differentiated cancer
cells.
Discussion
A plethora of reports have highlighted that FAK’s
expression levels and its activation correlate with the
initiation, progression, and the prognosis of a wide
variety of malignancies, and, thus, FAK has been
repeatedly proposed as an attractive target for cancer
therapy2–4,6,7,20. Subsequently, a number of laboratories
and pharmaceutical companies have invested into the
development of speciﬁc FAK-Is that are now evaluated
in pre-clinical animal models and in ﬁrst clinical
trials6,20–22. However, the actual mode of action of FAK
in tumor progression and metastasis and the biological
consequences of its pharmacological inhibition are still
poorly understood.
Here, we have used the novel and highly speciﬁc small-
molecule FAK-I BI 85352024 to repress FAK activity in
cultured breast cancer cells in vitro and in various pre-
clinical mouse models of breast cancer (Py2T, 4T1,
MTﬂECad/MTΔECad, and MMTV-PyMT) in vivo. BI
853520 elicits a substantial repression of cancer cell
proliferation and thus a repression of primary tumor
growth and outgrowth of metastatic lesions. However, BI
853520 does not diminish the actual metastatic dis-
semination of murine breast cancer cells, in contrast we
observe an increased number of pulmonary metastases
upon treatment with BI 853520 in an adjuvant setting
after surgical resection of 4T1 primary tumors.
Fig. 5 BI 853520 represses outgrowth of pulmonary metastases. a Top panel: Schematic overview of the experimental setup. Mice were either pre-
treated with BI 853520 3 days prior to 4T1 orthotopic tumor cell inoculation (Vehicle-PRE or BI 853520-PRE groups) or treated 7 days post 4T1
orthotopic tumor cell injection (Vehicle-POST or BI 853520-POST groups). Left bottom panel: Primary tumor growth in the indicated treatment
cohorts was monitored over time. BI 853520 treatment (BI 853520-PRE and BI 853520-POST) signiﬁcantly reduced primary tumor growth. Middle
bottom panel: Average numbers of individual pulmonary metastases per lung section. Only pre-treatment with BI 853520 decreased the numbers of
pulmonary metastases. Right bottom panel: Average metastatic area fraction (%) in pulmonary cross sections. Only pre-treatment with BI 853520
decreased the outgrowth of pulmonary metastases. n= 9, Vehicle-PRE; n= 9, BI 853520-PRE; n= 8, Vehicle-POST; n= 8, BI 853520-POST. Statistical
analysis was performed by unpaired, two-tailed Mann–Whitney U test (for tumor volumes) or unpaired, two-tailed Student’s t test (for number
metastases/section and metastasis area fraction). b Top panel: Schematic overview of the experimental setup. Mice were either pre-treated with BI
853520 3 days prior intravenous injection of 4T1 cells (Vehicle-PRE or BI 853520-PRE groups) or treated 3 days post intravenous injection of 4T1 cells
(Vehicle-POST or BI 853520-POST groups). Left bottom panel: Average numbers of pulmonary metastases per lung section. BI 853520 pre-treatment
signiﬁcantly decreased pulmonary metastases. Right bottom panel: Average metastatic area fraction (%) in pulmonary cross-sections. Both BI 853520
treatments (BI 853520-PRE and BI 853520-POST) signiﬁcantly reduced the metastatic area fraction. n= 5 for all treatment cohorts. Statistical analysis
was performed using unpaired, two-tailed Student’s t test. c Schematic overview of the experimental setup. 4T1 cells were orthotopically
transplanted into the mammary fat pad, followed by primary tumor removal 14 days post-injection and BI 853520 therapy in an adjuvant setting
2 days post surgery. Mice were sacriﬁced 38 days post injection. Left bottom panel: Average numbers of pulmonary metastases per lung section in an
adjuvant BI 853520 setting. BI 853520 signiﬁcantly increased the number of pulmonary metastases. Right bottom panel: Average metastatic area
fraction (%) in pulmonary cross-sections, with a trend of decrease following adjuvant BI 853520 therapy. n= 7, Vehicle; n= 5, BI 853520. Statistical
analysis was performed using unpaired, two-tailed Student’s t test. d Schematic overview of the experimental setup. 4T1 cells were orthotopically
transplanted into the mammary fat pad, followed by neoadjuvant BI 853520 therapy. Primary tumors were removed 14 days post injection and BI
853520 therapy was discontinued. Mice were sacriﬁced 32 days post injection. Left bottom panel: Primary tumor volumes. Right bottom panel:
Number of metastatic lesions per mouse. n= 5, Vehicle; n= 5, BI 853520. Statistical analysis was performed by Mann–Whitney U test for tumor
volumes and Student’s t test for lung metastases. ****p < 0.0001, ***p < 0.001. ns not signiﬁcant
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On the other hand, BI 853520 most effectively hampers
the establishment of pulmonary metastasis in mice har-
boring E-cadherin-deﬁcient (MTΔECad) tumors (Fig. 6c),
the metastatic outgrowth of 4T1 breast cancer cells with
downregulated E-cadherin expression (Fig. 2a), and the
3D Matrigel invasion of mesenchymal Py2T-LT cells (Fig.
1f and Suppl. Figure 2). Shapiro et al.33 have linked FAK-I
susceptibility of mesothelioma growth to merlin
deﬁciency. However, the Py2T, MTﬂECad, and MTΔE-
Cad cells employed here express similar levels of merlin,
and the susceptibility of Py2T and MTﬂECad tumors and
the insensitivity of MTΔECad tumors to BI 853520
appears to be independent of merlin expression status
(data not shown). Rather, our results suggest that the lack
or low expression of E-cadherin in 4T1 and MTΔECad
cells and in later stages of MMTV-PyMT tumor
Fig. 6 E-cadherin-dependent repression of metastasis formation by BI 853520. a Mice were orthotopically transplanted with E-cadherin-
expressing MTﬂECad or with E-cadherin-deﬁcient MTΔECad murine breast cancer cells. BI 853520 treatment was started at a primary tumor size of
100 mm3, and animals were sacriﬁced before the primary tumor reached a size of ~1500 mm3. BI 853520 signiﬁcantly increased survival of mice
transplanted with MTﬂECad cells, but not in mice transplanted with MTΔECad cells. b BI 853520 signiﬁcantly increases the mean time to reaching
termination criteria in mice transplanted with E-cadherin-proﬁcient MTﬂECad cells, but not in mice transplanted with E-cadherin-deﬁcient MTΔECad
cells. Statistical analysis was performed using a log-rank (Mantel–Cox) test. MTﬂECad: vehicle cohort, n= 8; BI 853520 cohort, n= 7. MTΔECad: vehicle
cohort, n= 5; BI 853520 cohort, n= 6. c BI 853520 reduces the average numbers of pulmonary metastases per lung section in the cohort of mice
bearing MTΔECad tumors. Vehicle cohort, n= 5; BI 853520 cohort, n= 6. Statistical analysis was performed using unpaired, two-tailed Student’s t test.
All data are depicted as mean ± SEM. ****p < 0.0001
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progression, and thus the invasive nature of the cancer
cells, may serve as a molecular biomarker for an anti-
metastatic activity of BI 853520. Intriguingly, this notion
stands in stark contrast to previous studies, where FAK
inhibition activates E-cadherin function and the reversal
of an EMT, thereby restraining the initiation and estab-
lishment of proliferative programs by micrometastatic cell
clusters and not affecting macrometastatic expansion34–
39. However, our histopathological analysis and gene
expression proﬁling of primary tumors treated or not with
BI 853520 have not revealed marked changes in the EMT
status of the breast cancer cells. Hence, further investi-
gations are warranted to decipher whether E-cadherin
expression can be used as a potential predictive marker
for the subset of patients that will respond to anti-
metastatic FAK-I therapy3,18,20,21. Notably, Hirt et al.24
have recently reported that the expression of hsa-miR-
200c-3p, an epithelial-speciﬁc microRNA efﬁciently
repressing EMT transcription factors and thus promoting
E-cadherin expression, strongly correlated with BI 853520
therapeutic efﬁcacy in a number of transplantation mouse
models of various cancer types. Confronted with these
seemingly conﬂicting results, we hypothesize that inter-
mediate stages of an EMT, such as a partial EMT with a
combination of epithelial and mesenchymal marker
expression, may represent a cell status of high cell plas-
ticity and metastasis and thus may be preferentially tar-
geted by FAK inhibition.
We have subsequently explored the direct biological
effects of FAK inhibition on tumor cells and characterized
potential mechanisms responsible for the signiﬁcant
decrease in tumor burden following BI 853520 adminis-
tration. RNA sequencing of primary murine breast tumors
treated with BI 853520 reveals a potent repression of
tumor cell proliferation and thus primary tumor growth.
Gene set enrichment analysis conﬁrms a signiﬁcant
reduction in the relative expression of genes important for
a positive regulation of mitotic cell cycle (including Cdk1
and Cdk4) and an increase in the expression of genes
relevant for a repression of the cell cycle. Previous studies
have indicated that ectopic expression of a constitutive-
active form of FAK leads to a rapid induction of pro-
liferation in murine mammary tumor cells, whereas a
decrease in FAK expression impairs their cell proliferation
in vitro and in vivo6,10,17,40. In line with these ﬁndings, BI
853520 treatment elicits a signiﬁcant reduction in murine
breast cancer cell proliferation in vitro and in vivo. These
ﬁndings are supported by ﬂow cytometry-based cell cycle
analysis where increasing concentrations of BI 853520 up
to 1 µM shift cells from the S phase to the G1 phase.
Together, the data suggest a linear mechanistic relation-
ship between FAK activity and murine breast cancer cell
proliferation.
Previously, it has been reported that tumor cells, which
have been genetically ablated for FAK expression or
treated with various FAK-I, undergo cell death6,17,20,41.
However, using immunoﬂuorescence analysis of primary
tumor sections and cellular assays, we have not observed a
signiﬁcant induction of apoptosis following BI 853520
treatment. We conclude that the most prominent ther-
apeutic effect observed by BI 853520 is based on its anti-
proliferative activities. Along these lines, the results
reported here also indicate that the kinase activity of FAK
is required for 4T1 murine breast cancer cell pulmonary
metastasis: the pharmacological inhibition of FAK kinase
activity by BI 853520 is consistent with the previously
reported ﬁndings that the kinase domain of FAK is
required for metastatic outgrowth of 4T1 cells42.
Although ongoing clinical trials with various FAK-I
seem encouraging and methods for patient stratiﬁcation
are planned, it is questionable whether FAK inhibition will
be used as a single-agent therapy, as it is the case for most
targeted therapies13,15,20. Previous studies have shown
that repression of FAK signaling in combination with
diverse chemotherapies enhanced chemo-cytotoxicity
in vitro and in vivo43–53. In line with FAK's role in an
anti-tumor evasion mechanism and an upregulated
immune response following BI 853520 treatment in the
4T1 breast cancer model (Fig. 3b), it has been shown in
mouse models of squamous cell cancer and pancreatic
ductal adenocarcinoma that FAK inhibition increases
immune surveillance, enhances the sensitivity to T cell
immunotherapy and treatment with PD-1 antagonists,
and ultimately delays tumor progression54–56. Future
efforts should be made to test BI 853520 and other FAK-I
in combination with chemotherapy or immunotherapy
reagents, thereby evaluating not only the anti-proliferative
effects but also the anti-metastatic effects of a combina-
tion therapy that might be applicable for various cancer
types3,22,41,57.
Materials and methods
Treatment of tumor transplantation and transgenic mouse
models
The murine metastatic cell line 4T1 is described else-
where28,58. Py2T cells have been derived from a breast
tumor of an MMTV-PyMT female mouse with an FVB/N
background25. E-cadherin-proﬁcient MTﬂECad cells have
been isolated from a lymph node metastasis of a MMTV-
Neu;Cdh1ﬂ/ﬂ tumor-bearing mouse and have been
infected with an adenovirus-expressing Cre recombinase
to obtain the E-cadherin-deﬁcient cell line MTΔECad29.
All cell lines were maintained in Dulbecco’s modiﬁed
Eagle's medium (DMEM), supplemented with fetal calf
serum (10%), glutamine (2 mM), penicillin (100 U; Sigma-
Aldrich), and streptomycin (0.2 mg/l; Sigma-Aldrich) in a
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humidiﬁed atmosphere of 37 °C, 5% CO2, and 95%
humidity.
Py2T, MTﬂECad, or MTΔECad cells (0.5 × 106) or
4T1 cells (1 × 106) suspended in 100 µl sterile phosphate-
buffered saline (PBS) were injected into mammary fat pad
number nine of anesthetized, 6–10-week-old female FVB/
N (Py2T cells), BALB/c (4T1 cells), Rag2−/−;γc−/−, or
nude mice (BALB/cAnN-Foxn1nu/nu/Rj; Janvier) mice
(MTﬂECad and MTΔECad cells). The length (D) and
width (d) of the tumors was measured by a digital caliper
every 2 to 3 days and the tumor volume was calculated
according the formula (V= 0.543 ×D x d2). Treatment
protocols were initiated several days after tumor cell
inoculation; the details are indicated in the respective
ﬁgure legends. BI 85352024 was dissolved in 0.5% hydro-
xyethylcellulose natrosol and administered at 50 mg/kg
body weight daily by oral gavage.
The MMTV-PyMT transgenic mouse model of meta-
static breast cancer was used to determine the therapeutic
and biological effect of BI 85352027,59,60. BI 853520 was
administered orally each day to mice of 5 weeks of age for
8 consecutive weeks, referred to as “early BI 853520”
treatment. In another cohort of mice, BI 853520 was
administered orally each day to mice of 10 weeks of age
for three consecutive weeks, referred to as “late BI
853520” treatment. All mice of this experimental setup
were sacriﬁced at 13 weeks of age and primary tumors and
lungs were used for further processing.
For RNA sequencing, BI 853520 was administered from
day 15 post injection for ﬁve consecutive days. To
determine whether BI 853520 pre-treatment is able to
prime the tumor microenvironment, mice were either
pre-treated 3 days prior tumor cell inoculation (Vehicle
PRE or BI 853520 PRE group) or BI 853520 was admi-
nistered 7 days (subcutaneous tumor cell injection) or
3 days (i.v. tumor cell injection) post tumor cell injection
(Vehicle POST or BI 853520 POST group).
For i.v. injection, 0.5 × 106 mouse 4T1 breast cancer
cells were injected into the tail vein of BALB/c mice.
To mimic the patient situation, BI 853520 was admi-
nistered in an adjuvant setting to the preclinical 4T1
breast cancer mouse model. For this purpose, primary
tumors were surgically removed 14 days after implanta-
tion of 4T1 cells in to the mammary fat pad, and BI
853520 therapy was started 2 days post surgery for the
consecutive 22 days.
For neoadjuvant BI 853520 treatment, BI 853520
administration was initiated 1 day after orthotopic tumor
cell implantation (1 × 106 4T1 cells mixed with Matrigel)
until primary tumor removal on days 14 or 15 post tumor
cell inoculation. Lung metastases were analyzed 32 days
post tumor cell inoculation.
When not speciﬁed otherwise, animals were sacriﬁced
when the maximum allowed primary tumor size of
1.5 cm3 was reached. For all experiments, primary tumors,
lungs, and peripheral blood were isolated and used for
further processing as previously described25,61. Primary
tumors in the abdominal mammary fat pad of MMTV-
PyMT mice were graded by using a Zeiss Axio Imager.Z2
microscope and ZEN 2 Zeiss Microscopy software (ver-
sion 2.0). Pulmonary cross-sections were imaged with a
×10 objective of a Zeiss Axio Imager.Z2 or a Zeiss Axio
Observer (Zeiss) microscope and the average amount of
unique pulmonary metastases as well as the average
metastatic area fraction (%) was quantiﬁed by using the
ImageJ software (ImageJ, Wayne Rasband, National
Institutes of Health, USA), ZEN 2 Zeiss Microscopy
software, or a customized application from Visiopharm.
All animal experiments were approved by and performed
according to the guidelines and legislation of the Swiss
Federal Veterinary Ofﬁce and the Cantonal Veterinary
Ofﬁce, Basel-Stadt, Switzerland (permit numbers 1878,
1907, and 1908).
BI 853520 treatment of breast cancer cells in vitro
For immunoblotting analysis, immunoﬂuorescence
staining (for phospho-H3 and cCasp3) and EdU/PI cell
cycle analysis, 1.3 × 105 4T1 cells were plated in a 6-cm
dish. For immunoﬂuorescence staining (for phospho-
Y397-FAK and total FAK), 3.3 × 104 4T1 cells were
plated in a 6-cm dish. For cell viability determination
following 96 h treatment with BI 853520, 0.5 × 103 4T1,
Py2T, and Py2T-LT cells were seeded in a 96-well for-
mat. 4T1, Py2T, and Py2T-LT cells were treated for the
indicated time points with varying concentrations of BI
853520.
Immunoblotting analysis
Tumor pieces were snap frozen and lysates were used
for immunoblotting analysis. Snap-frozen Py2T primary
tumor pieces were homogenized by a Polytron PT1200 E
(Kinematica AG) in lysis buffer (50 mM HEPES, pH 7.5,
150mM NaCl, 1% glycerol, 1% Triton X-100, 1.5 mM
MgCl2, 5 mM EGTA) supplemented with 0.1 mM sodium
orthovanadate (Sigma-Aldrich), 20 mM sodium ﬂuoride
(Sigma-Aldrich), and a protease inhibitor cocktail (Sigma-
Aldrich, 1:200). The lysates were cleared by centrifugation
and the protein content of supernatants was determined
by using Protein Assay Dye Reagent Concentrate (Bio-
Rad). Snap-frozen 4T1 primary tumor pieces were
homogenized by metal bead lysing matrix (MP Biomedi-
cals) in RIPA buffer (Sigma-Aldrich, 150mM NaCl, 1.0%
IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), 50 mM Tris, pH 8.0) sup-
plemented with 20mM sodium ﬂuoride (Sigma-Aldrich)
and a protease inhibitor cocktail (Sigma-Aldrich, 1:100).
4T1, Py2T, and Py2T-LT cells previously being treated
with BI 853520 were lysed in a sample solution (0.5M
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Tris-HCl, pH 6.8, 10% SDS, glycerol) or an NP40 buffer
(20 mM Tris, pH 7.5, 100mM NaCl, 5 mM MgCl2, 0.2%
NP40, 10% glycerol, 1 mM NaF, 20 mM β-glyceropho-
sphate, and freshly added 0.5 mM dithiothreitol/1× PIC
(Protease Inhibitor Cocktail) (Sigma)/1 mM vanadate).
The protein content was determined by the Pierce BCA
Protein Assay Kit (Thermo Scientiﬁc), loaded on 10%
SDS-polyacrylamide gel electrophoresis gels, and subse-
quently used for immunoblotting analysis. Following
blocking of the nitrocellulose blotting membranes (GE
Healthcare) for 1 h in 5% bovine serum albumin (BSA;
Sigma-Aldrich) dissolved in 0.1% Tween (Sigma-Aldrich)
in TBS (for Py2T tumors) or PBS (for 4T1 tumors),
membranes were incubated with primary antibodies:
mouse anti-FAK (Millipore, 05-537, clone 4.47), rabbit
anti-pFAK (Y397, Invitrogen, 44-624G), rabbit anti-PYK2
(Abcam, ab32571, clone YE353), and rabbit anti-pPYK2
(Y402, Abcam, ab4800) overnight at 4 °C. GAPDH (gly-
ceraldehyde 3-phosphate dehydrogenase) (Abcam, ab9485
or Sigma-Aldrich, G8795) or α-tubulin (Sigma-Aldrich,
T-9026, clone DM1A) were used as a loading control.
Membranes were then incubated for 1 h with horseradish
peroxidase-conjugated secondary antibodies (Jackson)
and subsequently visualized using Fusion Fx chemolu-
minescence reader (Vilber Lourmat) and Curix 60
(AGFA). For Py2T tumors, following visualization of the
pFAK signal, antibodies were removed by using a strip-
ping buffer (0.2 M glycin, pH 2.5, 0.1% SDS, 1% Tween)
two times 30min before initiating the staining procedure
against total FAK protein.
Immunoﬂuorescence staining of frozen sections
To prepare cryostat sections, organs were ﬁxed for 2 h
at 4 °C in 4% paraformaldehyde, incubated overnight in
20% sucrose in PBS (Sigma-Aldrich) at 4 °C, and then
embedded and snap frozen in OCT freezing matrix
(Tissue Tek). For immunoﬂuorescence analysis of frozen
sections, cryosections (7 µm thick) of tumor samples were
dried for 30min and rehydrated three times for 5 min in
PBS. After permeabilization for 20 min with 0.2% Triton
X-100 (Sigma-Aldrich) in PBS, slides were washed three
times for 5 min in PBS, blocked for 1 h at room tem-
perature in 5% goat serum diluted in PBS (blocking buf-
fer) for the phospho-H3 and CD31 staining and 20% goat
serum diluted in PBS for the cCasp3 staining, and incu-
bated overnight at 4 °C with primary antibodies (rabbit
anti-mouse phospho-H3, Millipore, 06-570; rat anti-
mouse CD31, BD Pharmingen, 550274; rabbit anti-
mouse cCasp3, Cell Signaling, 9664, clone 5A1E) diluted
in blocking buffer.
To detect perfused vessels, 150 µg of ﬂuorescein-labeled
Lycopersicon esculentum lectin (Vector Laboratories, GL-
1171) was injected i.v. and allowed to circulate for 20min.
Next, terminally anesthesized animals were perfused with
4% paraformaldehyde (PFA) in PBS followed by PBS via
the left cardiac ventricle.
For the detection of leaky blood vessels, 250 μg
ﬂuorescein-labeled dextran (70 kDa; Life Technologies,
D-1822) was injected i.v. in a tail vein and allowed to
circulate for 5 min. Then, terminally anesthesized animals
were perfused with PBS followed by a perfusion with 4%
PFA in PBS via the left cardiac ventricle.
Hypoxic areas were detected by injecting pimonidazole-
HCl (Hypoxyprobe Omni Kits, Hypoxyprobe, Inc.) at
60 mg/kg intraperitoneally 2 h prior to sacriﬁce of the
animals.
Immunoﬂuorescence stainings were revealed by incu-
bating slides for 1 h at room temperature with Alexa Fluor
488-labeled, Alexa Fluor 568-labeled, Alexa Fluor 633-
labeled, or Alexa Fluor 647-labeled secondary antibodies
(Invitrogen, 1:200) diluted in blocking buffer and washed
three times for 5 min in PBS. Nuclei were counterstained
for 10min with 4′,6-diamidino-2-phenylindole (DAPI,
Sigma-Aldrich, 1:5000) and slides were washed three
times for 5 min in PBS. Finally, slides were mounted in
DAKO ﬂuorescence mounting medium and evaluated
with a ×20 objective on a DMI 4000 microscope (Leica).
Images were processed and analyzed using the ImageJ
software (ImageJ, Wayne Rasband, National Institutes of
Health, USA).
Immunoﬂuorescence staining of cultured cells
4T1 cells grown on coverslips were ﬁxed for 20 min
with 4% PFA in PBS at room temperature. Subsequently,
cells were permeabilized for 10 min with 0.1% Triton X-
100 (Sigma-Aldrich) in PBS and blocked with 1% BSA
(Sigma-Aldrich) in PBS for 2 h. To visualize FAK and
pFAK expression, cells were incubated with the primary
antibodies mouse anti-FAK (Millipore, 05-537, clone
4.47), rabbit anti-pFAK (Y397, Invitrogen, 44-624G),
rabbit anti-mouse phospho-H3 (Millipore, 06-570), rabbit
anti-mouse cCasp3 (Cell Signaling, 9664, clone 5A1E)
diluted in 1% BSA in PBS overnight at 4 °C, followed by a
30-min incubation with DAPI (Sigma-Aldrich, 1:5000)
and Alexa Fluor 488-labeled or Alexa Fluor 568-labeled
secondary antibodies (Invitrogen, 1:200). The cells were
sealed by mounting them with Dako ﬂuorescence
mounting medium. Images were obtained using a Con-
focal SP5 microscope with a ×63 objective and a DFC 360
FX Monochromatic Camera (Leica) or with a ×10
(cCasp3) or ×20 objective (pH3) on a DMI 4000 micro-
scope (Leica).
In-gel immunoﬂuorescence staining
Growth factor-reduced Matrigel (Corning) was diluted
with ice-cold, serum-free growth medium (F12-HAM,
Sigma-Aldrich) to 4 mg/ml protein concentration by
gentle pipetting. Pellets of 1.5 × 103 4T1 cells and 2.5 × 103
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Py2T and Py2T-LT cells, respectively, were resuspended
in 10 µl 4 mg/ml Matrigel and seeded into each inner well
of a µ-slide angiogenesis microscopy slide (ibidi, Mar-
tinsried, Germany). Following 20min of gel solidiﬁcation
in a humidiﬁed atmosphere at 37 °C and 5% CO2, 30 µl of
normal growth medium (supplemented or not with 2 ng/
ml TGFβ) was added to each well. Growth medium was
refreshed every third day. After 5 days of culture, medium
containing increasing concentrations of BI 853520
(0.01 µM, 0.1 µM, and 1 µM) was added. The next day,
structures were ﬁxed in the matrix for 10min with 4%
PFA in PBS, washed for 5 min with 20mM glycine/PBS,
and permeabilized and blocked for 2 h at room tem-
perature in immunoﬂuorescence (IF) buffer (0.2% Triton
X-100/0.1% BSA/0.05% Tween-20/PBS) supplemented
with 10% goat serum. Samples were stained with primary
antibodies in IF buffer (rabbit anti-pFAK (Y397, Invitro-
gen, 44-624G); rabbit anti-ZO-1 (Zymed, 617300); mouse
anti-vimentin (Sigma-Aldrich, V2258)) for 2 h at room
temperature, washed twice with IF buffer, and incubated
with Alexa Fluor 488-labeled or Alexa Fluor 568-labeled
secondary antibodies diluted in IF buffer (Invitrogen,
1:200) for 45min. Nuclei were stained using DAPI
(Sigma-Aldrich, 1:5000) for 20 min at room temperature.
Following two washes with IF buffer, samples were
mounted with DAKO ﬂuorescent mounting medium and
imaged using a confocal microscope (SP5 confocal
microscope with a ×63 objective, Leica).
Cell proliferation assay
The effects of varying BI 853520 concentrations on cell
proliferation were determined by an MTS assay26 (Pro-
mega) according to the manufacturer’s protocol. Cells
were seeded, and 1 day later, varying concentrations of BI
853520 were added and cell viability was measured on day
5. Cell viability was measured using a SpectraMax 340
Microplate Reader (Molecular Devices) with a ﬁlter of
492 nm. For analysis, background absorbance from a “no-
cell” control row was subtracted from all measured values
and cell number of BI 853520-treated cells was normal-
ized to the dimethyl sulfoxide-treated controls.
Cell cycle analysis
For Edu/PI incorporation cell cycle analysis, 4T1 cells
were treated for 24 h with varying concentrations of BI
853520, and the cells were incubated for 5 min with
10 µM EdU (EdU Flow Cytometry Kit, baseclick). Har-
vested cells were subsequently ﬁxed for 15min with 4%
PFA in PBS at room temperature and permeabilized for
20min using 0.5% Triton X-100 (Sigma-Aldrich) in PBS
at room temperature. Following a 30 min incubation with
the click reaction containing the catalyst solution, the dye
azide, buffer additive, and PBS, cells were stained with PI
(Sigma-Aldrich) for 2 h at a humidiﬁed atmosphere of
37 °C and 5% CO2. Cell cycle distribution was analyzed by
using a BD FACSCANTO II analyzer and BD FACSDIVA
software (BD Biosciences).
Soft agar colony formation assay
A bottom layer of 1.5 ml 0.5% agarose/DMEM complete
growth medium per 6-well plate with 2 ng/ml TGFβ and
varying concentrations of BI 853520 was allowed to soli-
dify for 30min at room temperature. Three milliliters of
0.3% agarose/DMEM complete growth medium with 2 ×
104 Py2T-LT cells, 2 ng/ml TGFβ, and the target BI
853520 concentration were added on top and incubated
for 1.5 h in a tissue culture incubator. Finally, 1 ml DMEM
complete growth medium with 2 ng/ml TGFβ and the
target BI 853520 concentration was added on top. Every
4–6 days, 0.5 ml DMEM complete growth medium sup-
plemented with 2 ng/ml TGFβ and the target BI 853520
concentration was refreshed. After 18–21 days, colonies
were stained with MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide) solution (Sigma-
Aldrich) and quantiﬁed.
Apoptosis assay
Py2T and Py2T-LT cells (2 × 105) (constantly cultured
in the presence of 2 ng/ml TGFβ) were plated per 60mm
petri dish and allowed to adhere overnight. The next day,
BI 853520 at different concentrations was added. After
24 h of incubation with BI 853520, cells were trypsinized,
stained with Cy5 Annexin-V (BD Biosciences), and ana-
lyzed by ﬂow cytometry on a BD FACSCANTO II ana-
lyzer and BD FACSDIVA software (BD Biosciences).
Apoptotic cells were deﬁned as Annexin-V positive.
Matrigel invasion assay
Growth factor-reduced Matrigel (Corning) was diluted
with ice-cold serum-free DMEM (Sigma-Aldrich) by
gentle pipetting using pre-chilled pipette tips to 4 mg/ml
protein (100%) concentration. Ten microliters of Matrigel
was plated into each inner well of a µ-slide angiogenesis
microscopy slide (ibidi, Martinsried, Germany). The gel
was allowed to solidify for 45min in a humidiﬁed atmo-
sphere at 37 °C and 5% CO2. 4T1 cells (0.3 × 10
3) and
Py2T (1.25 × 103) epithelial murine breast cancer cells and
Py2T-LT mesenchymal cells, respectively, were seeded on
the gel, and then a top layer of growth medium with 10%
Matrigel, in the case for Py2T and Py2T-LT supple-
mented with twice the ﬁnal concentration of BI 853520
and 4 ng/ml TGFβ (for Py2T-LT), was added. Following
1 day of incubation in a humidiﬁed atmosphere at 37 °C
and 5% CO2, twice the ﬁnal concentration of BI 853520
was also added to the 4T1 cells. Medium containing 5%
Matrigel and BI 853520, and in the case of Py2T-LT cells
TGFβ, was replaced after 3 days, and after 6 days pictures
were taken using a Leica DMIL microscope.
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RNA isolation, RNA-sequencing library preparation,
sequencing, and data analysis
Snap-frozen mouse tumor pieces were homogenized in
Trizol (Sigma-Aldrich) and total RNA was isolated with
the RNeasy Lipid Tissue Mini Kit (Qiagen). Approxi-
mately 80 ng of total RNA was subsequently used for
TruSeq Stranded mRNA Library preparation on the
NeoPrep System (Illumina, San Diego, CA, USA) and
sequenced on the HiSeq1500 with the paired-end 50 cycle
protocol and the fast-output mode (Illumina, San Diego,
CA, USA). The RNA sequencing data are available under
GEO accession number GSE116117.
Paired-end RNA-sequencing (RNA-seq) reads were
mapped to the mouse genome assembly, version mm9,
with RNA-STAR62, with default parameters except that
only unique hits were aligned to the genome (out-
FilterMultimapNmax= 1) and that reads without evi-
dence in spliced junction table were ﬁltered
(outFilterType= “BySJout”). Using RefSeq mRNA coor-
dinates from UCSC (genome.ucsc.edu, downloaded in
July 2013) and the qCount function from QuasR package
(version 3.12.1)63, gene expression was quantiﬁed as the
number of reads that started within any annotated exon of
a gene. The differentially expressed genes were identiﬁed
using the edgeR package64. Genes with a p value smaller
than 0.05 and a minimum log 2 fold change of ±0.584
were considered statistically signiﬁcant and these genes
were subjected to downstream functional analysis.
Functional enrichment analysis
Functional enrichment analysis of differentially expres-
sed genes for biological processes65 or pathways was
performed in R using several publically available Bio-
conductor resources including GO.db (version 3.4.1),
GOstats (version 2.42.0)66, KEGG.db (version 3.2.3), and
ReactomePA (version 1.20.2)67. The signiﬁcance of each
biological processes or pathways identiﬁed was calculated
using the hypergeometric test (equivalent to Fisher’s exact
test). p Values ≤0.05 were considered statistically sig-
niﬁcant. Clustering and heatmaps of the enriched biolo-
gical processes were generated using hierarchical
clustering and distances between the clusters were com-
puted using the average linkage method.
Statistical analysis
Graphics and statistical analysis were performed using
the GraphPad Prism Software Version 7.0. When not
speciﬁed otherwise, the unpaired, two-tailed Student’s t
test or Mann–Whitney U test were applied (****p <
0.0001; ***p < 0.001; **p < 0.01; *p < 0.05) to determine
statistical signiﬁcance. Quantitative data were depicted as
means ± standard error of the mean (SEM).
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